These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 15558761

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Interventional closure with Amplatzer PFO occluder of patent foramen ovale in patients with paradoxical cerebral embolism.
    Chatterjee T, Petzsch M, Ince H, Rehders TC, Körber T, Weber F, Schneider H, Auf der Maur C, Nienaber CA.
    J Interv Cardiol; 2005 Jun; 18(3):173-9. PubMed ID: 15966921
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Second transcatheter closure for residual shunt following percutaneous closure of patent foramen ovale.
    Susuri N, Obeid S, Ulmi M, Siontis GCM, Wahl A, Windecker S, Nietlispach F, Meier B, Praz F.
    EuroIntervention; 2017 Sep 20; 13(7):858-866. PubMed ID: 28437244
    [Abstract] [Full Text] [Related]

  • 5. Clinical outcomes of patent foramen ovale closure for paradoxical emboli without echocardiographic guidance.
    Varma C, Benson LN, Warr MR, Yeo E, Yip J, Jaigobin CS, Webb G, McLaughlin PR.
    Catheter Cardiovasc Interv; 2004 Aug 20; 62(4):519-25. PubMed ID: 15274165
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Closure of patent foramen ovale for paradoxical emboli: intermediate-term risk of recurrent neurological events following transcatheter device placement.
    Hung J, Landzberg MJ, Jenkins KJ, King ME, Lock JE, Palacios IF, Lang P.
    J Am Coll Cardiol; 2000 Apr 20; 35(5):1311-6. PubMed ID: 10758974
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Improvement of migraine headaches after percutaneous closure of patent foramen ovale for secondary prevention of paradoxical embolism.
    Wahl A, Praz F, Tai T, Findling O, Walpoth N, Nedeltchev K, Schwerzmann M, Windecker S, Mattle HP, Meier B.
    Heart; 2010 Jun 20; 96(12):967-73. PubMed ID: 20538672
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Percutaneous closure of patent foramen ovale in patients with presumed paradoxical embolism: periprocedural results and midterm risk of recurrent neurologic events.
    Balbi M, Casalino L, Gnecco G, Bezante GP, Pongiglione G, Marasini M, Del Sette M, Barsotti A.
    Am Heart J; 2008 Aug 20; 156(2):356-60. PubMed ID: 18657668
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Long term follow up after percutaneous closure of PFO in 357 patients with paradoxical embolism: Difference in occlusion systems and influence of atrial septum aneurysm.
    von Bardeleben RS, Richter C, Otto J, Himmrich L, Schnabel R, Kampmann C, Rupprecht HJ, Marx J, Hommel G, Münzel T, Horstick G.
    Int J Cardiol; 2009 May 01; 134(1):33-41. PubMed ID: 18715659
    [Abstract] [Full Text] [Related]

  • 16. Transcatheter closure of patent foramen ovale associated with paradoxical embolism using the amplatzer PFO occluder: initial and intermediate-term results of the U.S. multicenter clinical trial.
    Hong TE, Thaler D, Brorson J, Heitschmidt M, Hijazi ZM, Amplatzer PFO Investigators.
    Catheter Cardiovasc Interv; 2003 Dec 01; 60(4):524-8. PubMed ID: 14624434
    [Abstract] [Full Text] [Related]

  • 17. [Interventional occlusion of foramen ovale and atrial septal defects after paradoxical embolism incidents].
    Beitzke A, Schuchlenz H, Beitzke M, Gamillscheg A, Stein HI, Zartner P.
    Z Kardiol; 2002 Sep 01; 91(9):693-700. PubMed ID: 12448068
    [Abstract] [Full Text] [Related]

  • 18. Long-term results after fluoroscopy-guided closure of patent foramen ovale for secondary prevention of paradoxical embolism.
    Wahl A, Kunz M, Moschovitis A, Nageh T, Schwerzmann M, Seiler C, Mattle HP, Windecker S, Meier B.
    Heart; 2008 Mar 01; 94(3):336-41. PubMed ID: 17639093
    [Abstract] [Full Text] [Related]

  • 19. Initial experience with the novel patent foramen ovale occlusion device Nit-Occlud® in patients with stroke or transient ischemic attack.
    Steinberg DH, Bertog SC, Momberger J, Franke J, Hofmann I, Renkhoff K, Joy S, Vaskelyte L, Sievert H.
    Catheter Cardiovasc Interv; 2015 Jun 01; 85(7):1262-7. PubMed ID: 24948394
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.